• Significant progress in clinical development program with multiple trials progressing
• Prioritizing high-value projects and clinical programs with high probabilities of success
• Completed $203.6 million placement to strengthen balance sheet and fund commercialization

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, has released its Appendix 4E Preliminary Final Report for the year ended 30 June 2025. The company made significant progress in its clinical development program, with a number of clinical trials progressing and releasing exciting data. Clarity also continued building its Discovery Platform to bring novel solutions to more patient populations and finalized manufacturing agreements for large-scale production. The company is prioritizing the development of 64/67Cu-SAR-bisPSMA for diagnostic and therapeutic applications in prostate cancer, as well as 64Cu-SARTATE in neuroendocrine tumours and 64Cu-SAR-Bombesin in breast and prostate cancers. Clarity's lead product, SAR-bisPSMA, is actively progressing through four clinical trials, including a theranostic trial (SECuRE) and two Phase III diagnostic trials (AMPLIFY and CLARIFY). The company also shared positive topline data for 64Cu-SARTATE and 64Cu-SAR-Bombesin from diagnostic Phase II trials. Clarity remains well-funded, having completed a $203.6 million placement in July 2025, providing a pro-forma cash balance of approximately $277 million as of 30 June 2025.

The company reported a loss of $64.3 million for the year ended 30 June 2025, up 52% from the prior year. Research and development expenditure increased by $21.1 million to $66.9 million, reflecting an increase in clinical trial activities.

Clarity remains focused on progressing its pipeline of preclinical and clinical assets, as well as executing its regulatory and operational objectives. The company is well-positioned to continue advancing its products towards commercialization with the strengthened balance sheet following the $203.6 million placement.